AQR Capital Management
STLN

AQR Capital Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

AQR Capital Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$137K Sell
44,519
-3,553
-7% -$10.9K ﹤0.01% 3658
2025
Q4 		$171K Buy
48,072
+4,007
+9% +$14.9K ﹤0.01% 3388
2025
Q3 		$154K Buy
+44,065
New +$151K ﹤0.01% 3311

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management's STLN Position: Q1 2026 in Review

AQR Capital Management reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 7.4% in Q1 2026, selling an estimated $10.9K and leaving 44,519 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #3658.

AQR Capital Management first reported a position in STLN in Q3 2025 and has held it in 3 quarters since. The position peaked at $171K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • AQR Capital Management held 44,519 shares of Starling Oncology Institute, Inc. Common Stock worth $137K as of Q1 2026.
  • AQR Capital Management sold 3,553 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $10.9K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3658 holding.
  • AQR Capital Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2025 and has held it in 3 quarters since.
  • AQR Capital Management's Starling Oncology Institute, Inc. Common Stock position peaked at $171K in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.